Drug com­pa­nies rack up prof­its at ex­pense of cus­tomers, com­pe­ti­tion

Kyiv Post Legal Quarterly - - Contents - BY ISO­BEL KOSHIW IVKOSHIW@GMAIL.CO M

In con­trast to the sickly Ukrainian econ­omy, many of the coun­try’s phar­ma­ceu­ti­cal com­pa­nies are mak­ing healthy prof­its.

Ukraine’s top phar­ma­ceu­ti­cal pro­ducer, Far­mak, re­cently re­ported that it had al­most dou­bled prof­its in 2015 com­pared to 2014, and in March the com­pany an­nounced a 61-per­cent in­crease in div­i­dend pay­ments to share­hold­ers.

Like­wise, Darnytsa – Ukraine’s sec­ond big­gest drug man­u­fac­turer – an­nounced on April 25 that it had in­creased its rev­enues by 34 per­cent in the first quar­ter, and had earned a to­tal of Hr 519 million ($20 million) thus far in 2016. Ac­cord­ing to the Ukrainian State Sta­tis­tics Ser­vice, the over­all out­put of the do­mes­tic drug in­dus-

Work­ers pro­duce in­sulin at an In­dar fac­tory in Kyiv on March 13, 2013. In­dar is one of the big­gest pro­duc­ers of the drug in Ukraine. (UNIAN)

Newspapers in English

Newspapers from Ukraine

© PressReader. All rights reserved.